Siddiqi, T., Frankel, P., Beumer, J. H., Kiesel, B. F., Christner, S., Ruel, C., . . . Newman, E. M. (2019). Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma.
Citação norma ChicagoSiddiqi, Tanya, et al. "Phase 1 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) Combined With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies." Leuk Lymphoma 2019.
Citação norma MLASiddiqi, Tanya, et al. "Phase 1 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) Combined With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies." Leuk Lymphoma 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.